Inactive Instrument

Analyst Reco. Theravance Inc Nasdaq

Equities

US88338T1043

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Apr. 24	Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc.?s Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024	CI
Mar. 04	Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morgan Stanley Adjusts Price Target on Innoviva to $10 From $13, Maintains Underweight Rating	23-03-03	MT
Morgan Stanley Adjusts Price Target on Innoviva to $14 From $13, Maintains Underweight Rating	22-10-13	MT
Goldman Sachs Starts Innoviva at Neutral With $16 Price Target	22-07-20	MT
Morgan Stanley Trims Innoviva's Price Target to $12 From $13, Underweight Rating Maintained	22-07-15	MT
Morgan Stanley Raises Innoviva's Price Target to $13 From $12, Maintains Underweight Rating	22-04-12	MT
Morgan Stanley Raises Innoviva's Price Target to $12 From $10, Maintains Underweight Rating	22-02-23	MT
INNOVIVA : Morgan Stanley Adjusts Innoviva PT to $10 From $8, Maintains Underweight Rating	20-11-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer